DRNK Revenue third quarter 2014 Y/Y Growth Comment
Noho, Inc. reported Revenue surge of 65.44% year on year in the third quarter 2014, to $ 0.28 millions, this is lower than Noho, Inc.'s recent average Revenue rise of 69.47%.
Looking into third quarter 2014 results within Biotechnology & Pharmaceuticals industry 20 other companies have achieved higher Revenue growth. While Noho, Inc.' s Revenue jump of 65.44% ranks overall at the positon no. 466 in the third quarter 2014.
Revenue by Quarter for the Fiscal Years 2011, 2012, 2013, 2014
Noho,'s Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
173.87 %
53.37 %
-68.41 %
(Dec 31 2013)
DRNK's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2014 Noho, Inc. disclosed growth in Revenue from the second quarter by 0.45% to $ 0.28 millions, from $ 0.28 millions achived in the previous reporting period.
Within Biotechnology & Pharmaceuticals industry 56 other companies have achieved higher Revenue quarter on quarter growth. While Noho,'s Revenue growth quarter on quarter, overall rank is 2642.
In the III. Quarter 2014 Noho, Inc. disclosed growth in Revenue from the second quarter by 0.45% to $ 0.28 millions, from $ 0.28 millions achived in the previous reporting period.
Within Biotechnology & Pharmaceuticals industry 56 other companies have achieved higher Revenue quarter on quarter growth. While Noho,'s Revenue growth quarter on quarter, overall rank is 2642.
Noho,'s 12 Months Revenue Growth Year on Year
Revenue TTM Growth
12 Months Ending (Sep 30 2014)
12 Months Ending (Jun 30 2014)
12 Months Ending (Mar 31 2014)
12 Months Ending (Dec 31 2013)
12 Months Ending (Sep 30 2013)
Cumulative Revenue 12 Months Ending
$ 1.18
$ 1.07
$ 0.88
$ 0.98
$ 0.00
Y / Y Revenue Growth (TTM)
-
-
-
-
-
Year on Year Revenue Growth Overall
Ranking
#
#
#
#
#
Seqeuential Revenue Change (TTM)
10.45 %
20.77 %
-9.91 %
-
-
Seq. Revenue Growth (TTM) Overall
Ranking
# 1265
# 527
# 0
# 0
# 0
Cumulative Revenue growth Comment
Noho, saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 65.44% year on year, to $ 1 millions if the fiscal year would have ended in Sep 30 2014. Noho,'s trailing twelve months Revenue growth was higher than company's average 0% and higher than % growth in Jun 30 2014. And, Noho, realized the fastest Revenue growth, in Biotechnology & Pharmaceuticals industry. But from twelve months ended Jun 30 2014 rise was beneth at 10.45 % from $1.07 millions achieved in the period from Jun 30 2014 to Sep 30 2013. Still this was evidence of convincing trend, while the usual Q/Q TTM gain stands at 0%. The momentum is even more impressive from twelve months ended Jun 30 2014 exhibited at 10.45 % increase from $1.07 millions in the period from Jun 30 2014 to Sep 30 2013.
Noho, Inc. achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .
Noho, saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 65.44% year on year, to $ 1 millions if the fiscal year would have ended in Sep 30 2014. Noho,'s trailing twelve months Revenue growth was higher than company's average 0% and higher than % growth in Jun 30 2014. And, Noho, realized the fastest Revenue growth, in Biotechnology & Pharmaceuticals industry. But from twelve months ended Jun 30 2014 rise was beneth at 10.45 % from $1.07 millions achieved in the period from Jun 30 2014 to Sep 30 2013. Still this was evidence of convincing trend, while the usual Q/Q TTM gain stands at 0%. The momentum is even more impressive from twelve months ended Jun 30 2014 exhibited at 10.45 % increase from $1.07 millions in the period from Jun 30 2014 to Sep 30 2013.
Noho, Inc. achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .
About Noho, Revenue Growth Rates (DRNK), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
112.67%